OPEN END TURBO LONG - INCYTE CO. Share Price

DE000MB9ELQ8

Market Closed - Börse Stuttgart 20:53:47 28/06/2024 BST
2.04 ^EUR	-5.12%

Current month	+10.87%
1 month	+15.91%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart INCYTE CORPORATION

Latest news about INCYTE CORPORATION

InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients	06-21	AQ
Incyte Insider Sold Shares Worth $1,149,840, According to a Recent SEC Filing	06-14	MT
Incyte Reports Tender Offer Results	06-13	MT
Tranche Update on Incyte Corporation's Equity Buyback Plan announced on May 13, 2024.	06-13	CI

More news

Quotes 5-day view

Date	Price	Change
28/06/24	2.04	-5.12%
27/06/24	2.15	-3.15%
26/06/24	2.22	-4.72%
25/06/24	2.33	-2.10%
24/06/24	2.38	-0.83%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 08:53 pm

More quotes

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	CALL
Underlying	INCYTE CORPORATION
Issuer	Morgan Stanley
WKN	MB9ELQ
ISIN	DE000MB9ELQ8
Date issued	02/08/2023
Strike	38.3 $
Maturity	Unlimited
Parity	10 : 1
Emission price	2.66 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.87 €
Lowest since issue	1.19 €

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

More about the company

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Incyte Corporation

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

60.62 USD

Average target price

72.8 USD

Spread / Average Target

+20.09%

Consensus